New Delhi, Apr 20 (PTI) The Competition Commission of India (CCI) on Thursday said it has cleared Berhyanda Ltd's acquisition of a 76.10 per cent stake in pharmaceutical firm Suven Pharmaceuticals Ltd.

Berhyanda Ltd is a wholly-owned subsidiary of Berhyanda Midco Ltd, which is an affiliate of Advent International Corporation.

Also Read | How To Get Blue Tick on Twitter? As Elon Musk Sets To Remove Verified Checkmarks From Legacy Accounts, Know Verification Requirements and Steps To Get Blue Checkmark.

The proposed combination relates to the acquisition by Berhyanda Ltd for up to 76.10 per cent of the voting share capital of Suven Pharmaceuticals Ltd, by way of a share purchase agreement dated December 26, 2022, and pursuant to the mandatory open offer in compliance with Sebi's SAST (Substantial Acquisition of Shares and Takeovers) regulations, according to an official release.

Suven Pharmaceuticals Ltd is a biopharmaceutical company that offers its services to global pharmaceutical and agrochemical majors.

Also Read | What Is Layoff? Know the Definition and Meaning of the Term That Is Making Major Headlines in 2023.

Deals beyond a certain threshold require approval from the regulator, which keeps a tab on unfair business practices in the marketplace.

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)